Clarametyx Biosciences, Inc.
Columbus, OH
- UEI
- V756DHVLXLK4
- CAGE
- 8LJU0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1275 Kinnear Rd #111a, Columbus, OH 43212, USA
- Website
- clarametyx.com
- Founded
- 2020
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $384,727 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a multi-species vaccine for prevention of bacterial otitis media | National Institute on Deafness and Other Communincation Disorders (NIH) | $5,878,533 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Novobiotic Pharmaceuticals, LLC | Cambridge, MA | 238990 All Other Specialty Trade Contractors |
| Curza Inc. | Salt Lake City, UT | — |
| Trellis Bioscience, Inc. | — | — |
| Lumen Bioscience, Inc. | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cmtx Biotech Inc. | Kings Park, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Clarametyx Biosciences, Inc. is a preclinical stage biotechnology company developing immune enabling biologic therapies to fight life threatening infections. Their novel technology platform targets the protective barrier around bacteria, known as biofilms.
Clarametyx Biosciences, Inc. has received one prime federal grant award from the National Institutes of Health to support studies needed to optimize the research and development precursor of CMTX-301 into a clinically-viable vaccine candidate for prevention of bacterial otitis media. The studies include evaluating formulations of CMTX-301 with FDA approved adjuvants and then testing the lead and backup formulations for relative protective efficacy in chinchilla and rat models of otitis media caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae. The award also supports evaluation of dose regimen and schedule as well as safety evaluation and GMP manufacturing to support an Investigational New Drug application with the FDA.
Clarametyx Biosciences, Inc. has received two federal contract sub-awards to support the development of anti-biofilm monoclonal antibodies CMTX-101 and CMTX-001 for rapidly collapsing bacterial biofilms to enable more effective bacterial clearance when used with antibiotic therapy. The sub-awards from Boston University aim to develop these monoclonal antibodies for empiric therapy to treat moderate to severe bacterial pneumonia in hospitalized patients. The sub-awards also fund characterization of a lead clinical candidate and initial development of a manufacturing process for clinical supplies.
Quick answers
Is Clarametyx Biosciences, Inc. registered in SAM.gov?
Yes. Clarametyx Biosciences, Inc.'s SAM.gov registration is active through August 31, 2027.
What is Clarametyx Biosciences, Inc.'s most recent federal award?
Clarametyx Biosciences, Inc.'s most recent federal grant award is Development of a multi-species vaccine for prevention of bacterial otitis media (R44DC019874), from National Institute on Deafness and Other Communincation Disorders (NIH), on January 1, 2022.
On GovTribe
See Clarametyx Biosciences, Inc.'s full federal record
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors